Business Context and Reporting Period
Company: Advanced Biomed Inc. (ADVB)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: Advanced Biomed Inc. is a Nevada holding company primarily operating through its Taiwan subsidiary, focusing on R&D for microfluidic biochip technologies for oncology detection. The company has no substantive revenue-generating operations as of the reporting date. During the period, the company completed the disposal of its Hong Kong subsidiary (Advanced Biomed HK Limited) and its clinical-related business segment, which is now reported as discontinued operations. Subsequent to the period end, the company acquired Acellent Technologies (Hong Kong) Co. Limited, signaling a strategic pivot toward AI-powered financial audit solutions.
Key Financial Metrics
| Metric | Three Months Ended March 31, 2026 |
Nine Months Ended March 31, 2026 |
Nine Months Ended March 31, 2025 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Income (Loss) | $(488,942) | $5,982,078 | $(2,557,358) |
| Net Income (Loss) from Continuing Ops | $(488,942) | $6,254,557 | $(1,762,106) |
| Operating Expenses | $(519,836) | $(1,311,353) | $(1,075,149) |
| Cash and Cash Equivalents | $2,602,697 (as of March 31, 2026) | ||
| Working Capital | $9,100,625 (as of March 31, 2026) | ||
| Total Liabilities | $1,436,587 (as of March 31, 2026) | ||
| Net Cash Used in Operating Activities | $(1,363,675) (Nine Months 2026) |
Material Changes vs. Prior Period
- Net Income Turnaround: The company reported a net income of $5.98 million for the nine months ended March 31, 2026, compared to a net loss of $2.56 million in the prior year. This reversal is primarily attributable to a one-time gain on disposal of subsidiaries of $7.35 million recognized in the period.
- Discontinued Operations: Results from the Hong Kong subsidiary (market development and clinical-related business) are now classified as discontinued operations. The company recognized a loss from discontinued operations of $272,479 for the nine months ended March 31, 2026, compared to $795,252 in the prior year.
- Operating Expenses: Total operating expenses increased by 22% year-over-year for the nine-month period ($1.31 million vs. $1.08 million), driven by a 36% increase in General and Administrative expenses (due to higher professional fees and staff costs) and an 11% increase in R&D expenses.
- Foreign Exchange: Other income improved significantly due to a foreign exchange gain of $210,132 in the current nine-month period, compared to a loss of $702,244 in the prior year.
- Capital Structure: The company effected a 1-for-20 reverse stock split on February 20, 2026. All share and per-share data have been retroactively adjusted.
Guidance, Outlook, and Risks
- Going Concern: Management has disclosed substantial doubt regarding the company's ability to continue as a going concern. Despite the reported net income, the company continues to experience negative operating cash flows ($1.36 million outflow for the nine months ended March 31, 2026). The net income is non-recurring due to the asset sale.
- Liquidity Strategy: To sustain operations, the company plans to raise additional capital, utilize an existing Equity Line of Credit (ELOC) agreement for up to $25 million, and seek financial support from related parties. A private placement in January 2026 raised $248,000.
- Strategic Pivot: Following the disposal of its Hong Kong subsidiary, the company acquired Acellent Technologies (Hong Kong) Co. Limited in April 2026 (subsequent event). This marks a strategic shift from oncology R&D to AI-powered financial audit solutions.
- Regulatory Status: The company has no approved products for sale. Its oncology products (e.g., A+Pre, AC-1000) are in various stages of regulatory review with the NMPA in China. The company expects to remain in a state of continuous loss for the next two to three years regarding its original business plan.
- Risks: Key risks include the inability to secure additional financing, failure to obtain regulatory approvals for medical devices, and the uncertainty of the new strategic direction in financial audit solutions.
Investor Verification Checklist
- Verify the Sustainability of Net Income: Confirm that the $5.98 million net income is entirely driven by the one-time $7.35 million gain on the sale of the Hong Kong subsidiary and does not reflect operational profitability.
- Assess Cash Burn Rate: Review the negative operating cash flow of $1.36 million for the nine-month period against the current cash balance of $2.6 million to determine the runway without further financing.
- Confirm Strategic Pivot Details: Investigate the terms and financial impact of the subsequent acquisition of Acellent Technologies (Hong Kong) Co. Limited and the appointment of Xiaomin Chen as CEO.
- Review Related Party Transactions: Examine the $712,353 in amounts due to related parties (major stockholders and related corporations) and the terms of the ELOC agreement.
- Check Regulatory Progress: Verify the current status of NMPA registration for the oncology products (A+Pre, AC-1000, A+LCGuard) to assess the viability of the original business model.